Sunshine Biopharma (SBFM) Shares Jump 66% Pre-Market After Reverse Split, Canadian Approval for Rivaroxaban

Sunshine Biopharma Inc. (NASDAQ: SBFM) shares surged 66% in pre-market trading on June 2, 2026, after the company completed a reverse stock split and received Health Canada approval to market generic rivaroxaban, a widely prescribed blood thinner. The dual announcements provided a sharp uplift to the micro-cap biotech’s stock, which had been trading below $1 prior to the actions. The reverse split, intended to regain Nasdaq compliance, consolidated outstanding shares, while the Canadian regulatory nod allows the company to launch a lower-cost version of Bayer’s Xarelto. Rivaroxaban is used to prevent strokes and blood clots, generating billions in annual global sales. Sunshine Biopharma now plans to commercialize the generic through its Canadian sales channels. No U.S. approval timeline was disclosed.